There are 2137 resources available
160O - Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)
Presenter: Andreas Schneeweiss
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA12 - PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer
Presenter: Erica Mayer
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
161O - Randomized preoperative window of opportunity (WOO) study with the CDK4/6 inhibitor abemaciclib in early breast cancer (EBC) patients and differential gene expression pathway analyses with palbociclib
Presenter: Monica Arnedos
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
1913O - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Presenter: Mimi Hu
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
CN20 - Oral targeted therapy dose adaptation in geriatric cancer patients: A real life French cohort
Presenter: Fanny Leenhardt
Session: EONS13: Phase I clinical trials: What does this mean for our patients?
Resources:
Abstract
Slides
Webcast
1257O - Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
Presenter: David Hong
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
1258O - Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
Presenter: Byoung Chul Cho
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
LBA50 - ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)
Presenter: Li Zhang
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
1259O - A randomized phase II study of osimertinib with or without bevacizumab in advanced lung adenocarcinoma patients with EGFR T790M mutation (West Japan Oncology Group 8715L)
Presenter: Yukihiro Toi
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
LBA41 - LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours
Presenter: Zarnie Lwin
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast